What we are studying
Renal cell cancer is a type of kidney cancer that starts in the lining of very small tubes in the kidney. Like other cancers, renal cell cancer begins small and grows larger over time. For the cancer growth, new blood vessels need to form to supply nutrients to the cancer cells. Drugs that target the development of blood vessels that feed the tumor have shown significant effect to suppress cancer activity. These drugs have become the standard of care for the treatment of patients with advanced renal cell cancer.
Tivozanib is a drug that blocks the development of blood vessels that trigger the cancer cells to divide and grow. Tivozanib is being investigated in clinical studies. Results from the completed studies suggest that tivozanib is generally well tolerated.
The purpose of this study is to compare the effectiveness of tivozanib in renal cell cancer compared to an approved drug “sorafenib” which works in a similar way to tivozanib. Tivozanib and sorafenib are both called “study medication”. This study will also see whether tivozanib is safe and tolerable for patients with advanced renal cell cancer.